查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1439599

全球經導管心臟瓣膜置換裝置市場：洞察、競爭格局、市場預測：2030 年

Transcatheter Heart Valve Replacement Devices - Market Insights, Competitive Landscape, and Market Forecast - 2030
出版日期: | 出版商: DelveInsight | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

預計 2024 年至 2030 年期間，全球經導管心臟瓣膜置換裝置市場規模將以 13.75% 的複合年增長率擴大。 經導管心臟瓣膜置換裝置市場的成長主要是由全球瓣膜性心臟病和主動脈瓣狹窄發生率的增加所推動的。 此外，人們越來越關注微創手術，設備和手術技術不斷進步，老年人口的負擔也越來越重，他們更容易患上主動脈瓣狹窄、二尖瓣逆流和其他心血管疾病以及瓣膜性心臟病。導致經導管心臟瓣膜的風險因素負擔增加、管道中存在大量設備、產品上市和批准增加以及主要進入者的投資急劇增加，預計將在預測期內增加經導管心臟瓣膜的數量2024- 2030年。預計將對需求產生影響。

推動經導管心臟瓣膜置換裝置市場的關鍵因素之一是，由於主動脈瓣狹窄的高盛行率，對經導管心臟瓣膜置換裝置的需求不斷增加。

例如，根據世界衛生組織 (WHO) 的數據，2020 年全球鈣化性主動脈瓣狹窄盛行率為 900 萬人。 另外，根據John Muir Health統計，2020年美國將有約150萬人患有主動脈瓣狹窄，其中約50萬人患有重度主動脈瓣狹窄。 據同一消息來源稱，2020 年美國約有 25 萬名主動脈瓣狹窄患者出現症狀。

根據歐洲心臟學會 2020 年的數據，退化性鈣化性主動脈瓣狹窄在高收入國家非常常見（盛行率 12.4%）。 根據同一消息來源，2020 年歐洲和美國 75 歲以上人口中重度主動脈瓣狹窄的盛行率約為 3.4%。 此外，這種疾病是美國第二常見的瓣膜疾病，到 2020 年將影響約 5% 的 65 歲人口。 由於主動脈瓣狹窄在全球範圍內呈上升趨勢，預計市場對經導管心臟瓣膜的需求將會增加。

本報告研究了全球經導管心臟瓣膜置換裝置市場，並提供了市場概述，包括按產品、應用、最終用戶、地區以及參與市場的公司概況劃分的趨勢。

目錄

第1章經導管心臟瓣膜置換裝置市場報告簡介

第 2 章經導管心臟瓣膜置換裝置市場執行摘要

第3章監理分析

  • 美國
  • 歐洲
  • 日本
  • 中國

第4章經導管心臟瓣膜置換裝置市場主要因素分析

  • 經導管心臟瓣膜置換設備市場驅動因素
  • 經導管心臟瓣膜置換裝置市場的限制與挑戰
  • 經導管心臟瓣膜置換裝置的市場機會

第5章波特對經導管心臟瓣膜置換裝置市場的五力分析

第6章COVID-19對經導管心臟瓣膜置換設備市場的影響分析

第7章經導管心臟瓣膜置換裝置市場概述

  • 按產品
  • 依用途
  • 按最終用戶
  • 按地區

第8章經導管心臟瓣膜置換裝置市場的公司與產品概況

  • Medtronic
  • Boston Scientific Corporation
  • Bracco SpA
  • Edward Lifesciences
  • Meril Lifesciences
  • JenaValve Technologies Inc.
  • Venus Medtech (Hangzhou) Inc.
  • Abbott
  • Bluesail Medical Co., Ltd.
  • Braile Biomedica
  • CryoLife, Inc.
  • SMT
  • Peijia Medical Limited
  • P+F Products + Features GmbH
  • Livanova Plc

第9章KOL瀏覽量

第 10 章專案方法

第 11 章關於 DelveInsight

第 12 章免責聲明與聯絡我們

Product Code: DIMDCL0431

Transcatheter Heart Valve Replacement Market By Product (Transcatheter Aortic Valve Replacement, Transcatheter Mitral Valve Replacement, And Transcatheter Pulmonary Valve Replacement), By Application (Aortic Valve Stenosis, Aortic Valve Regurgitation, Mitral Valve Stenosis, Mitral Valve Regurgitation, And Others), By End-User (Hospitals, Specialty Clinics, And Others) and by geography is expected to advance at a respectable CAGR forecast till 2030 owing to the growing number valvular disease, aortic stenosis disorder, among other cardiovascular disorders and the presence of robust number of devices in pipeline across the globe

The global transcatheter heart valve replacement market is estimated to grow at a CAGR of 13.75% during the forecast period from 2024 to 2030. The transcatheter heart valve replacement market is observing significant market growth primarily owing to the growing number of valvular heart diseases, and aortic stenosis disorders across the globe. Further, the rising focus on minimally invasive surgeries, increasing technological advancements in device & surgical procedures, the increasing burden of the geriatric population prone to aortic stenosis, mitral regurgitation, and other cardiovascular disorders, increasing burden of risk factors leading to valvular diseases, presence of a large number of devices in the pipeline, increasing product launches and approvals, surging investments by key players, among others will ultimately affect the demand for transcatheter heart valve during the forecast period from 2024-2030 growing at a substantial CAGR.

Transcatheter Heart Valve Replacement Market Dynamics:

One of the key aspects driving the transcatheter heart valve replacement market is the increasing demand for transcatheter heart valve replacement owing to the high prevalence of aortic stenosis disorder.

For instance, according to the World Health Organization 2020, the prevalence of calcific aortic valve stenosis was 9 million across the world. Also, as per the John Muir Health statistics, in the year 2020, about 1.5 million people in the United States suffered from aortic stenosis and about 500,000 people within this group of patients suffered from severe aortic stenosis. As per the same source in 2020, about 250,000 patients suffering from aortic stenosis were symptomatic in the United States.

Degenerative calcific aortic stenosis is found to be very common (with a prevalence of 12.4%) in high-income countries, according to the European Society of Cardiology, 2020. According to the same source, the prevalence of severe aortic stenosis in people over the age of 75 in Europe and the United States was around 3.4% in 2020. Furthermore, the disease is the second most common valvular lesion in the United States, affected approximately 5% of the population at the age of 65 in 2020. Because of the global increase in aortic stenosis cases, there will be a high demand for trans-catheter heart valves in the market.

Further, increasing technological advancements, rising product launches & approvals, and other strategic activities by the key players will propel the market of overall transcatheter heart valve replacement. For instance, in December 2022, Abbott, launched its latest-generation transcatheter aortic valve implantation (TAVI) system, Navitor, making the minimally invasive device available for people in India with severe aortic stenosis who are at high or extreme surgical risk.

Also, in January 2020, Jenavalve transcatheter aortic valve replacement system had been designated as a breakthrough device designation by US FDA for severe aortic regurgitation (AR) and AR-dominant mixed aortic valve disease.

Therefore, the factors stated above collectively will drive the overall transcatheter heart valve replacement market during the forecast period from 2024-2030.

However, the high cost of the devices and surgical procedure, the presence of alternative treatment options in the market, the risk associated with the replacement process, and others may prove to be challenging factors for the transcatheter heart valve replacement market growth.

The transcatheter heart valve replacement market was significantly impacted during the period of the COVID-19 pandemic. During the initial stage of the pandemic, the demand for transcatheter heart valve replacement devices suffered a downfall owing to the imposition of strict lockdown rules, and disruption in manufacturing, and supply. Moreover, owing to the diversion of the medical field towards dining COVID-19, the funding for R&D activities related to cardiac diseases was been diminished and many non-urgent surgeries were also postponed, thereby declining the demand for transcatheter heart valve replacement in the market. However, with the ease of lockdown restrictions, the upturn of resources and supply chain, the administration of a vaccine to the public, and the return of patients to hospitals for surgeries, the demand for transcatheter heart valve replacement increased and is anticipated to do the same during the forecast period from 2022 - 2028.

Transcatheter Heart Valve Replacement Market Segment Analysis:

Transcatheter Heart Valve Replacement Market by Product (Transcatheter Aortic Valve Replacement, Transcatheter Mitral Valve Replacement, and Transcatheter Pulmonary Valve Replacement), Application (Aortic Valve Stenosis, Aortic Valve Regurgitation, Mitral Valve Stenosis, Mitral Valve Regurgitation, and Others), End-User (Hospitals, Specialty Clinics, And Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World).

In the product segment of the transcatheter heart valve replacement market, the transcatheter aortic valve replacement (TAVR) segment is expected to have a significant revenue share in the year 2023. This was primarily owing to the increasing cases of aortic stenosis disorder as TAVR is the first-line surgical procedure performed for aortic stenosis. Further, the availability of technologically advanced devices in the market, and rising device launches and approvals will also affect the market positively.

For instance, according to the American Heart Association, approximately 1.5 million people in the United States had aortic valve stenosis in020. The same source stated that approximately 100,000 patients had undergone TAVR procedures in the United States, compared to only 50,000 patients who have opted for open surgery for aortic valve replacement in the United States in 2020.

Also in 2019, TAVR procedures were initially indicated for patients with severe symptomatic aortic stenosis who were not fit for surgical treatment, as determined by the Heart Valve team, but newer guidelines have approved the treatment of TAVR in intermediate-risk aortic stenosis patients.

Additionally, the approval and launch of devices for transcatheter aortic valve replacement devices will lead to an increase in the demand for transcatheter heart valve replacement devices. In September 2022, the United States Food and Drug Administration approved Abbott's Portico with FlexNav transcatheter aortic valve replacement (TAVR) system for the treatment of individuals suffering from symptomatic, and severe aortic stenosis.

Therefore, owing to the above-mentioned advantages, the category is expected to witness considerable growth eventually contributing to the overall growth of the transcatheter heart valve replacement market.

North America is expected to dominate the overall Transcatheter Heart Valve Replacement Market:

Among all the regions, North America is expected to dominate global transcatheter heart valve replacement in the year 2023 and is expected to do the same during the forecast period from 2024-2030. This domination is attributed to the high prevalence of cardiovascular diseases such as aortic stenosis, aortic regurgitation, among others, rise in transcatheter heart valve replacement device approvals and launches, and others are the key factor contributing to the transcatheter heart valve replacement devices market in the region and are expected to aid in the growth of the North America transcatheter heart valve replacement devices market.

For instance, according to the American Heart Association, in the year 2020, 20% of older Americans suffered from aortic stenosis. It is common in people over the age of 65 years and if left untreated can cause heart failure and death. Owing to the increase in the prevalence of patients suffering from aortic stenosis, there will be an increase in the demand for transcatheter heart valve replacement devices.

Further, according to the Centers for Disease Control and Prevention (CDC) 2022, heart disease is the leading cause of death for men, women, and people in the United States. According to the same source, one person die every 36 seconds from cardiovascular diseases and about 6,59,000 people die due to heart diseases every year, in the region, which is about one in four deaths.

Lastly, the rising product approvals and launches in North America will also increase the demand for transcatheter heart valve replacement. For instance, in September 2019, Medtronic plc announced U.S. Food and Drug Administration (FDA) approval and U.S. launch of the Evolut(TM) PRO+ TAVR System - a new-generation Medtronic TAVR system that builds off the proven self-expanding, supra-annular Evolut TAVR platform.

Also, in July 2019, Abbott received U.S. Food and Drug Administration (FDA) approval for the most advanced MitraClip(TM) heart valve repair device to treat mitral regurgitation.

Therefore, the interplay of the aforementioned factors above would provide a conducive growth environment for the North American region in the transcatheter heart valve replacement market.

Transcatheter Heart Valve Replacement Market Key Players:

Some of the key market players operating in the transcatheter heart valve replacement market include Medtronic, Boston Scientific Corporation, Bracco SpA, Edward Lifesciences, Meril Lifesciences, JenaValve Technologies Inc., Venus Medtech (Hangzhou) Inc., Abbott, Bluesail Medical Co., Ltd., Braile Biomedica, CryoLife, Inc., SMT, Peijia Medical Limited, P+F Products + Features GmbH, Livanova Plc, and others.

Recent Developmental Activities in the Transcatheter Heart Valve Replacement Market:

In January 2022, Medtronic plc announced that the National Medical Products Administration (NMPA) approved the CoreValve Evolut PRO TAVR system for the treatment of severe aortic stenosis (AS) for symptomatic patients in China who are at high or extreme risk for open heart surgery.

In September 2022, Abbott announced that Food and Drug Administration (FDA) has approved the company's Portico(TM) with FlexNav(TM) transcatheter aortic valve replacement (TAVR) system to treat people with symptomatic, severe aortic stenosis who are at high or extreme risk for open-heart surgery.

In April 2020, Abbott received CE Mark for its next-generation TriClip Transcatheter Tricuspid Valve Repair System, the first-of-its-kind minimally invasive tricuspid heart valve repair device available in Europe to treat tricuspid regurgitation (TR). The clip-based therapy, known as TriClip G4, is a non-surgical heart valve repair option specifically designed for the treatment of TR, or a leaky tricuspid valve, that allows physicians to tailor repair of the valve to each patient's unique anatomy.

Key Takeaways from the Transcatheter Heart Valve Replacement Market Report Study

Market size analysis for current transcatheter heart valve replacement market size (2023), and market forecast for 5 years (2024-2030)

The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the transcatheter heart valve replacement market.

Top key product/services/technology developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years

Key companies dominating the global transcatheter heart valve replacement market.

Various opportunities available for the other competitor in the transcatheter heart valve replacement market space.

What are the top-performing segments in 2023? How these segments will perform in 2030.

Which are the top-performing regions and countries in the current transcatheter heart valve replacement market scenario?

Which are the regions and countries where companies should have concentrated on opportunities for transcatheter heart valve replacement market growth in the coming future?

Target Audience who can be benefited from this Transcatheter Heart Valve Replacement Market Report Study

Transcatheter heart valve replacement products providers

Research organizations and consulting companies

Transcatheter heart valve replacement-related organizations, associations, forums, and other alliances

Government and corporate offices

Start-up companies, venture capitalists, and private equity firms

Distributors and Traders dealing in transcatheter heart valve replacement

Various end users who want to know more about the transcatheter heart valve replacement market and the latest technological developments in the transcatheter heart valve replacement market.

Frequently Asked Questions for the Transcatheter Heart Valve Replacement Market:

1. What is transcatheter heart valve replacement?

Transcatheter heart valve replacement is a procedure with a less invasive approach that helps replace the heart valve with a prosthetic valve to treat severe aortic stenosis and mitral regurgitation. It is an effective alternative to cumbersome open heart surgery, especially for high-risk patients.

2. What is the global market for transcatheter heart valve replacement?

The global transcatheter heart valve replacement market is estimated to grow at a CAGR of 13.75% during the forecast period from 2024 to 2030.

3. What are the drivers for the global transcatheter heart valve replacement market?

The transcatheter heart valve replacement market is witnessing positive market growth owing to the factors such as the growing number of valvular diseases, aortic stenosis disorders across the globe, the rising focus on minimally invasive surgeries, and increasing technological advancements in device and surgical procedures, the increasing burden of the geriatric population prone to aortic stenosis, mitral regurgitation, and other cardiovascular disorders, presence of a large number of devices in the pipeline, increasing product launches and approvals, and others will create an exigency for the transcatheter heart valve replacement market.

4. Who are the key players operating in the global transcatheter heart valve replacement market?

Some of the key market players operating in the transcatheter heart valve replacement market include Medtronic, Boston Scientific Corporation, Bracco SpA, Edward Lifesciences, Meril Lifesciences, JenaValve Technologies Inc., Venus Medtech (Hangzhou) Inc., Abbott, Bluesail Medical Co., Ltd., Braile Biomedica, CryoLife, Inc., SMT, Peijia Medical Limited, P+F Products + Features GmbH, Livanova Plc, and others.

5. Which region has the highest share of the transcatheter heart valve replacement market?

Among all the regions, North America is estimated to amass a significant revenue share in the global transcatheter heart valve replacement market. This can be ascribed to the transcatheter heart valve replacement manufacturers in the US, the growing number of valvular diseases, aortic stenosis disorder, surging burden of the geriatric population, increasing product launches and approvals, and others act as a supportive factor for the North America transcatheter heart valve replacement market growth.

Table of Contents

1.Transcatheter Heart Valve Replacement Market Report Introduction

2. Transcatheter Heart Valve Replacement Market Executive Summary

  • 2.1. Scope of the Study
  • 2.2. Market at Glance
  • 2.3. Competitive Assessment

3. Regulatory Analysis

  • 3.1. The United States
  • 3.2. Europe
  • 3.3. Japan
  • 3.4. China

4. Transcatheter Heart Valve Replacement Market Key Factors Analysis

  • 4.1. Transcatheter Heart Valve Replacement Market Drivers
    • 4.1.1. The growing number of valvular heart diseases such as aortic stenosis disorders, and others across the globe
    • 4.1.2. Rising focus on minimally invasive surgeries and increasing technological advancements in device and surgical procedure
    • 4.1.3. The increasing burden of the geriatric population prone to aortic stenosis, mitral regurgitation, and other cardiovascular disorders
    • 4.1.4. Presence of a favorable reimbursement scenario
  • 4.2. Transcatheter Heart Valve Replacement Market Restraints and Challenges
    • 4.2.1. High cost of the device and surgical procedure
    • 4.2.2. Presence of alternative treatment in the market
    • 4.2.3. Risks associated with the replacement process
  • 4.3. Transcatheter Heart Valve Replacement Market Opportunities
    • 4.3.1. Growing manufacturer interest in emerging countries is leading to the spiked sale of transcatheter heart valve
    • 4.3.2. Presence of a large number of devices in the pipeline

5. Transcatheter Heart Valve Replacement Market Porter's Five Forces Analysis

  • 5.1. Bargaining Power of Suppliers
  • 5.2. Bargaining Power of Consumers
  • 5.3. Threat of New Entrants
  • 5.4. Threat of Substitutes
  • 5.5. Competitive Rivalry

6. COVID-19 Impact Analysis on Transcatheter Heart Valve Replacement Market

7. Transcatheter Heart Valve Replacement Market Layout

  • 7.1. By Product
    • 7.1.1. Transcatheter Aortic Valve Replacement
    • 7.1.2. Transcatheter Mitral Valve Replacement
    • 7.1.3. Transcatheter Pulmonary Valve Replacement
  • 7.2. By Application
    • 7.2.1. Aortic Valve Stenosis
    • 7.2.2. Aortic Valve Regurgitation
    • 7.2.3. Mitral Valve Stenosis
    • 7.2.4. Mitral Valve Regurgitation
    • 7.2.5. Others
  • 7.3. By End-User
    • 7.3.1. Hospitals
    • 7.3.2. Specialty Clinics
    • 7.3.3. Others
  • 7.4. By Geography
    • 7.4.1. North America
      • 7.4.1.1. United States Transcatheter Heart Valve Replacement Market in USD million (2021-2030)
      • 7.4.1.2. Canada Transcatheter Heart Valve Replacement Market in USD million (2021-2030)
      • 7.4.1.3. Mexico Transcatheter Heart Valve Replacement Market in USD million (2021-2030)
    • 7.4.2. Europe
      • 7.4.2.1. France Transcatheter Heart Valve Replacement Market in USD million (2021-2030)
      • 7.4.2.2. Germany Transcatheter Heart Valve Replacement Market in USD million (2021-2030)
      • 7.4.2.3. United Kingdom Transcatheter Heart Valve Replacement Market in USD million (2021-2030)
      • 7.4.2.4. Italy Transcatheter Heart Valve Replacement Market in USD million (2021-2030)
      • 7.4.2.5. Spain Transcatheter Heart Valve Replacement Market in USD million (2021-2030)
      • 7.4.2.6. Rest of Europe Transcatheter Heart Valve Replacement Market in USD million (2021-2030)
    • 7.4.3. Asia-Pacific
      • 7.4.3.1. China Transcatheter Heart Valve Replacement Market in USD million (2021-2030)
      • 7.4.3.2. Japan Transcatheter Heart Valve Replacement Market in USD million (2021-2030)
      • 7.4.3.3. India Transcatheter Heart Valve Replacement Market in USD million (2021-2030)
      • 7.4.3.4. Australia Transcatheter Heart Valve Replacement Market in USD million (2021-2030)
      • 7.4.3.5. South Korea Transcatheter Heart Valve Replacement Market in USD million (2021-2030)
      • 7.4.3.6. Rest of Asia Pacific Transcatheter Heart Valve Replacement Market in USD million (2021-2030)
    • 7.4.4. Rest of the World (RoW)
      • 7.4.4.1. Middle East Transcatheter Heart Valve Replacement Market in USD million (2021-2030)
      • 7.4.4.2. Africa Transcatheter Heart Valve Replacement Market in USD million (2021-2030)
      • 7.4.4.3. South America Transcatheter Heart Valve Replacement Market in USD million (2021-2030)

8. Transcatheter Heart Valve Replacement Market Company and Product Profiles

  • 8.1. Medtronic
    • 8.1.1. Company Overview
    • 8.1.2. Company Snapshot
    • 8.1.3. Financial Overview
    • 8.1.4. Product Listing
    • 8.1.5. Entropy
  • 8.2. Boston Scientific Corporation
    • 8.2.1. Company Overview
    • 8.2.2. Company Snapshot
    • 8.2.3. Financial Overview
    • 8.2.4. Product Listing
    • 8.2.5. Entropy
  • 8.3. Bracco SpA
    • 8.3.1. Company Overview
    • 8.3.2. Company Snapshot
    • 8.3.3. Financial Overview
    • 8.3.4. Product Listing
    • 8.3.5. Entropy
  • 8.4. Edward Lifesciences
    • 8.4.1. Company Overview
    • 8.4.2. Company Snapshot
    • 8.4.3. Financial Overview
    • 8.4.4. Product Listing
    • 8.4.5. Entropy
  • 8.5. Meril Lifesciences
    • 8.5.1. Company Overview
    • 8.5.2. Company Snapshot
    • 8.5.3. Financial Overview
    • 8.5.4. Product Listing
    • 8.5.5. Entropy
  • 8.6. JenaValve Technologies Inc.
    • 8.6.1. Company Overview
    • 8.6.2. Company Snapshot
    • 8.6.3. Financial Overview
    • 8.6.4. Product Listing
    • 8.6.5. Entropy
  • 8.7. Venus Medtech (Hangzhou) Inc.
    • 8.7.1. Company Overview
    • 8.7.2. Company Snapshot
    • 8.7.3. Financial Overview
    • 8.7.4. Product Listing
    • 8.7.5. Entropy
  • 8.8. Abbott
    • 8.8.1. Company Overview
    • 8.8.2. Company Snapshot
    • 8.8.3. Financial Overview
    • 8.8.4. Product Listing
    • 8.8.5. Entropy
  • 8.9. Bluesail Medical Co., Ltd.
    • 8.9.1. Company Overview
    • 8.9.2. Company Snapshot
    • 8.9.3. Financial Overview
    • 8.9.4 Product Listing
    • 8.9.5. Entropy
  • 8.10. Braile Biomedica
    • 8.10.1. Company Overview
    • 8.10.2. Company Snapshot
    • 8.10.3. Financial Overview
    • 8.10.4. Product Listing
    • 8.10.5. Entropy
  • 8.11. CryoLife, Inc.
    • 8.11.1. Company Overview
    • 8.11.2. Company Snapshot
    • 8.11.3. Financial Overview
    • 8.11.4. Product Listing
    • 8.11.5. Entropy
  • 8.12. SMT
    • 8.12.1. Company Overview
    • 8.12.2. Company Snapshot
    • 8.12.3. Financial Overview
    • 8.12.4. Product Listing
    • 8.12.5. Entropy
  • 8.13. Peijia Medical Limited
    • 8.13.1. Company Overview
    • 8.13.2. Company Snapshot
    • 8.13.3. Financial Overview
    • 8.13.4. Product Listing
    • 8.13.5. Entropy
  • 8.14. P+F Products + Features GmbH
    • 8.14.1. Company Overview
    • 8.14.2. Company Snapshot
    • 8.14.3. Financial Overview
    • 8.14.4. Product Listing
    • 8.14.5. Entropy
  • 8.15. Livanova Plc
    • 8.15.1. Company Overview
    • 8.15.2. Company Snapshot
    • 8.15.3. Financial Overview
    • 8.15.4. Product Listing
    • 8.15.5. Entropy

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us

List of Tables

  • Table 1: Competitive Analysis
  • Table 2: COVID-19 Impact Analysis on Transcatheter Heart Valve Replacement Market
  • Table 3: Transcatheter Heart Valve Replacement Market Analysis in Global (2021-2030)
  • Table 4: Transcatheter Heart Valve Replacement Market Analysis in Global by Product (2021-2030)
  • Table 5: Transcatheter Heart Valve Replacement Market Analysis in Global by Application (2021-2030)
  • Table 6: Transcatheter Heart Valve Replacement Market Analysis in Global by End-User (2021-2030)
  • Table 7: Transcatheter Heart Valve Replacement Market Analysis in Global by Geography (2021-2030)
  • Table 8: Transcatheter Heart Valve Replacement Market Analysis in North America (2021-2030)
  • Table 9: Transcatheter Heart Valve Replacement Market Analysis in North America by Country (2021-2030)
  • Table 10: Transcatheter Heart Valve Replacement Market Analysis in the US (2021-2030)
  • Table 11: Transcatheter Heart Valve Replacement Market Analysis in Canada (2021-2030)
  • Table 12: Transcatheter Heart Valve Replacement Market Analysis in Mexico (2021-2030)
  • Table 13: Transcatheter Heart Valve Replacement Market Analysis in Europe (2021-2030)
  • Table 14: Transcatheter Heart Valve Replacement Market Analysis in Europe by Country (2021-2030)
  • Table 15: Transcatheter Heart Valve Replacement Market Analysis in France (2021-2030)
  • Table 16: Transcatheter Heart Valve Replacement Market Analysis in Germany (2021-2030)
  • Table 17: Transcatheter Heart Valve Replacement Market Analysis in the UK (2021-2030)
  • Table 18: Transcatheter Heart Valve Replacement Market Analysis in Italy (2021-2030)
  • Table 19: Transcatheter Heart Valve Replacement Market Analysis in Spain (2021-2030)
  • Table 20: Transcatheter Heart Valve Replacement Market Analysis in the Rest of Europe (2021-2030)
  • Table 21: Transcatheter Heart Valve Replacement Market Analysis in Asia-Pacific (2021-2030)
  • Table 22: Transcatheter Heart Valve Replacement Market Analysis in Asia-Pacific by Country (2021-2030)
  • Table 23: Transcatheter Heart Valve Replacement Market Analysis in China (2021-2030)
  • Table 24: Transcatheter Heart Valve Replacement Market Analysis in Japan (2021-2030)
  • Table 25: Transcatheter Heart Valve Replacement Market Analysis in India (2021-2030)
  • Table 26: Transcatheter Heart Valve Replacement Market Analysis in Australia (2021-2030)
  • Table 27: Transcatheter Heart Valve Replacement Market Analysis in South Korea (2021-2030)
  • Table 28: Transcatheter Heart Valve Replacement Market Analysis in the Rest of Asia-Pacific (2021-2030)
  • Table 29: Transcatheter Heart Valve Replacement Market Analysis in the Rest of the World (2021-2030)
  • Table 30: Transcatheter Heart Valve Replacement Market Analysis in the Rest of the World by Region (2021-2030)
  • Table 31: Transcatheter Heart Valve Replacement Market Analysis in the Middle East (2021-2030)
  • Table 32: Transcatheter Heart Valve Replacement Market Analysis in Africa (2021-2030)
  • Table 33: Transcatheter Heart Valve Replacement Market Analysis in South America (2021-2030)

List of Figures

  • Figure 1: Competitive Analysis
  • Figure 2: COVID-19 Impact Analysis on Transcatheter Heart Valve Replacement Market
  • Figure 3: Transcatheter Heart Valve Replacement Market Analysis in Global (2021-2030)
  • Figure 4: Transcatheter Heart Valve Replacement Market Analysis in Global by Product (2021-2030)
  • Figure 5: Transcatheter Heart Valve Replacement Market Analysis in Global by Application (2021-2030)
  • Figure 6: Transcatheter Heart Valve Replacement Market Analysis in Global by End-User (2021-2030)
  • Figure 7: Transcatheter Heart Valve Replacement Market Analysis in Global by Geography (2021-2030)
  • Figure 8: Transcatheter Heart Valve Replacement Market Analysis in North America (2021-2030)
  • Figure 9: Transcatheter Heart Valve Replacement Market Analysis in North America by Country (2021-2030)
  • Figure 10: Transcatheter Heart Valve Replacement Market Analysis in the US (2021-2030)
  • Figure 11: Transcatheter Heart Valve Replacement Market Analysis in Canada (2021-2030)
  • Figure 12: Transcatheter Heart Valve Replacement Market Analysis in Mexico (2021-2030)
  • Figure 13: Transcatheter Heart Valve Replacement Market Analysis in Europe (2021-2030)
  • Figure 14: Transcatheter Heart Valve Replacement Market Analysis in Europe by Country (2021-2030)
  • Figure 15: Transcatheter Heart Valve Replacement Market Analysis in France (2021-2030)
  • Figure 16: Transcatheter Heart Valve Replacement Market Analysis in Germany (2021-2030)
  • Figure 17: Transcatheter Heart Valve Replacement Market Analysis in the UK (2021-2030)
  • Figure 18: Transcatheter Heart Valve Replacement Market Analysis in Italy (2021-2030)
  • Figure 19: Transcatheter Heart Valve Replacement Market Analysis in Spain (2021-2030)
  • Figure 20: Transcatheter Heart Valve Replacement Market Analysis in the Rest of Europe (2021-2030)
  • Figure 21: Transcatheter Heart Valve Replacement Market Analysis in Asia-Pacific (2021-2030)
  • Figure 22: Transcatheter Heart Valve Replacement Market Analysis in Asia-Pacific by Country (2021-2030)
  • Figure 23: Transcatheter Heart Valve Replacement Market Analysis in China (2021-2030)
  • Figure 24: Transcatheter Heart Valve Replacement Market Analysis in Japan (2021-2030)
  • Figure 25: Transcatheter Heart Valve Replacement Market Analysis in India (2021-2030)
  • Figure 26: Transcatheter Heart Valve Replacement Market Analysis in Australia (2021-2030)
  • Figure 27: Transcatheter Heart Valve Replacement Market Analysis in South Korea (2021-2030)
  • Figure 28: Transcatheter Heart Valve Replacement Market Analysis in the Rest of Asia-Pacific (2021-2030)
  • Figure 29: Transcatheter Heart Valve Replacement Market Analysis in the Rest of the World (2021-2030)
  • Figure 30: Transcatheter Heart Valve Replacement Market Analysis in the Rest of the World by Region (2021-2030)
  • Figure 31: Transcatheter Heart Valve Replacement Market Analysis in the Middle East (2021-2030)
  • Figure 32: Transcatheter Heart Valve Replacement Market Analysis in Africa (2021-2030)
  • Figure 33: Transcatheter Heart Valve Replacement Market Analysis in South America (2021-2030)
  • Figure 34: Market Drivers
  • Figure 35: Market Barriers
  • Figure 36: Market Opportunities
  • Figure 37: PORTER's Five Force Analysis